 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1718192021222324252627...208209» |
- | AiTan (rivoceranib) / HLB Bio Group, Yondelis (trabectedin) / PharmaMar, J&J, pazopanib / Generic mfg.
Review, Journal: Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma. (Pubmed Central) - Nov 26, 2025
IDH1 inhibition benefits conventional subtypes rather than MCS. Early immunotherapy experience is limited, but pathway-directed strategies targeting BCL2 and PI3K-mTOR warrant evaluation.
- | narsoplimab (OMS721) / Omeros, SHR-2010 / Jiangsu Hengrui Pharma
Journal: Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases. (Pubmed Central) - Nov 26, 2025
Preclinical studies demonstrated that SHR-2010 exhibited superior pharmacokinetics and sustained lectin pathway inhibition compared to OMS721. When coupled with optimized trial design strategies, SHR-2010 could be a promising therapeutic candidate for lectin pathway-driven diseases, including IgAN.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: HER2-targeted therapy combined with multidisciplinary management in advanced gallbladder cancer: a case report with 90-month survival. (Pubmed Central) - Nov 26, 2025
Dynamic CA199 levels paralleled the treatment efficacy. This report underscores the significance of molecular profiling-guided personalized therapy and integrated multidisciplinary management in the treatment of biliary tract cancers.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
Enrollment closed: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) - Nov 25, 2025
P2, N=88, Active, not recruiting, Sponsor: Fudan University
This report underscores the significance of molecular profiling-guided personalized therapy and integrated multidisciplinary management in the treatment of biliary tract cancers. Recruiting --> Active, not recruiting
- | Retrospective data, Journal: Efficacy and safety of adebrelimab plus bevacizumab in combination with hepatic artery infusion chemotherapy for advanced stage hepatocellular carcinoma: a retrospective cohort study. (Pubmed Central) - Nov 25, 2025
Only one case (3.1%) had a grade 3 treatment-related adverse event (rash), which could be alleviated after symptomatic management. The combination of adebrelimab, bevacizumab, and HAIC-FOLFOX demonstrated encouraging results and manageable safety concerns for patients with HCC at BCLC stage C.
- ||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Clinical, P3 data, Retrospective data, Journal: Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial. (Pubmed Central) - Nov 25, 2025
P3
The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments. Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.
- ||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment closed, Trial primary completion date: HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Nov 24, 2025
P2, N=203, Active, not recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jan 2026
- | Review, Journal, PD(L)-1 Biomarker, IO biomarker: Optimizing Transarterial Chemoembolization in Hepatocellular Carcinoma: Current Strategies, Innovations, and Future Directions. (Pubmed Central) - Nov 24, 2025
Despite its established role, TACE is not without risks, including post-embolization syndrome and organ-specific ischemic complications. Continued research is essential to refine selection criteria, minimize adverse effects, and validate innovative approaches, ultimately improving outcomes for HCC patients across diverse clinical scenarios.
- | AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Real-world evidence: Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study. (Pubmed Central) - Nov 24, 2025
In patients with R/M NPC that progressed after first-line therapy, the combination of anti-angiogenic agents (apatinib or anlotinib) with PD-1 inhibitors based therapy demonstrated a promising antitumor efficacy and an acceptable safety profile. These findings were consistent even among patients from non-endemic regions.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Oncaspar liquid (pegaspargase) / Servier
Retrospective data, Journal: Retrospective analysis of clinical characteristics, treatment outcomes and prognosis of patients with natural killer/T-cell lymphoma. (Pubmed Central) - Nov 24, 2025
In conclusion, the results indicated promising efficacy for pegaspargase-based chemotherapy in terms of response rates and survival outcomes for both early- and advanced-stage patients. However, further refinement of treatment strategies is needed.
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Journal: Ivarmacitinib: A Novel Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis-Letter to the Editor. (Pubmed Central) - Nov 24, 2025
However, further refinement of treatment strategies is needed. No abstract available
- |||||||| AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P3 trial: MA-PCa-III-021: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (clinicaltrials.gov) - Nov 22, 2025
P3, N=156, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | cyclosporine / Generic mfg., NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Journal: Corneal Staining Responder Analysis: A Clinically Meaningful Dry Eye Outcome. (Pubmed Central) - Nov 21, 2025
No abstract available This analysis demonstrates that a ?3 severity grade improvement in corneal staining score is consistently associated with significant corresponding symptom improvement and may represent a clinically meaningful DED outcome measure for clinical studies and patient care.
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: MA-UC-II-007: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (clinicaltrials.gov) - Nov 21, 2025
P2, N=96, Recruiting, Sponsor: Sun Yat-sen University
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Biocon, Biotech Pharma, HRS-4642 / Jiangsu Hengrui Pharma
New P2 trial: HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (clinicaltrials.gov) - Nov 21, 2025
P2, N=40, Not yet recruiting, Sponsor: Zhejiang University
- |||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
New P1/2 trial: Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov) - Nov 20, 2025
P1/2, N=139, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||| sonesitatug vedotin (AZD0901) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy: CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - Nov 20, 2025
P3, N=572, Recruiting, Sponsor: AstraZeneca
This analysis demonstrates that a ?3 severity grade improvement in corneal staining score is consistently associated with significant corresponding symptom improvement and may represent a clinically meaningful DED outcome measure for clinical studies and patient care. Trial completion date: Apr 2027 --> Sep 2026 | Trial primary completion date: Oct 2026 --> May 2026
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Checkpoint inhibition: Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment (clinicaltrials.gov) - Nov 20, 2025
P2, N=30, Recruiting, Sponsor: Sun Yat-sen University
- | morphine sulphate / Generic mfg., AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
Journal: The Analgesic Effect of Tegileridine in Older Adult Patients After Laparoscopic Abdominal Tumor Surgery: Study Protocol for a Randomized Controlled Trial. (Pubmed Central) - Nov 20, 2025
P=N/A
Registered at the Chinese Clinical Trial Registry on October 14, 2025. ChiCTR2500110485.
- | Tevimbra (tislelizumab-jsgr) / BeOne Medicines, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial, Head-to-Head: PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC (clinicaltrials.gov) - Nov 19, 2025
P3, N=260, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma (clinicaltrials.gov) - Nov 19, 2025
P2, N=30, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- |||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
Enrollment open: Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 18, 2025
P3, N=460, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
ChiCTR2500110485. Not yet recruiting --> Recruiting
- |||||||||| HRS-4642 / Jiangsu Hengrui Pharma
New P3 trial: HRS-4642-302: HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 18, 2025
P3, N=588, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || HRS-5041 / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov) - Nov 18, 2025
P1/2, N=100, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026
- ||| zeprumetostat (SHR-2554) / Treeline Biosci
Enrollment open: Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (clinicaltrials.gov) - Nov 18, 2025
P2, N=200, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026 Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: CORIN-PYRA: Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - Nov 18, 2025
P2, N=186, Recruiting, Sponsor: Wenjin Yin
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| HRS-7535 / Kailera Therapeutics
Trial completion, Enrollment change: Efficacy and Safety of HRS-7535 Tablets in Adults With Type 2 Diabetic Kidney Disease (clinicaltrials.gov) - Nov 18, 2025
P2, N=281, Completed, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | N=186 --> 281
- |||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity (clinicaltrials.gov) - Nov 18, 2025
P3, N=140, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Completed | N=186 --> 281 Not yet recruiting --> Recruiting
- ||| GSK5784283 / GSK
Enrollment change, Trial completion date, Trial primary completion date: A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Nov 17, 2025
P2, N=70, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting N=20 --> 70 | Trial completion date: Sep 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Sep 2026
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) - Nov 17, 2025
P2, N=60, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=20 --> 70 | Trial completion date: Sep 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Sep 2026 Not yet recruiting --> Recruiting
- ||||| zeprumetostat (SHR-2554) / Treeline Biosci, AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P2 trial: A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov) - Nov 17, 2025
P2, N=218, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| SHR-A2102 / Jiangsu Hengrui Pharma
New P2 trial: SHR-A2102-212: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 17, 2025
P2, N=300, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- |||||||||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
New P3 trial: SHR-1918-302: A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia (clinicaltrials.gov) - Nov 17, 2025
P3, N=900, Not yet recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial, Head-to-Head: Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery (clinicaltrials.gov) - Nov 17, 2025
P4, N=171, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- |||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer (clinicaltrials.gov) - Nov 17, 2025
P3, N=720, Recruiting, Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment closed: GASTO-10107: Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 17, 2025
P2, N=170, Active, not recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
New P3 trial: SHR-8068-303: A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (clinicaltrials.gov) - Nov 17, 2025
P3, N=604, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer (clinicaltrials.gov) - Nov 17, 2025
P3, N=650, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Journal, HEOR, Real-world evidence: Herbal analgesic patches versus NSAIDs in soft tissue injury management: real-world comparative effectiveness from a 35-center chinese prospective cohort of 1378 participants. (Pubmed Central) - Nov 17, 2025
GTP is a safe NSAIDs alternative, especially for patients with comorbidities. Monotherapy or a 2-week SCI-to-GTP transition is recommended because of the lack of combination synergy.
- | Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Observational data, Journal, Real-world evidence: Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITP. (Pubmed Central) - Nov 15, 2025
However, critical evidence gaps persist regarding treatment-switching strategies between TPO-RAs, particularly when transitioning from eltrombopag (ELT) or hetrombopag (HET) to AVA...AVA demonstrates potential as a safe and effective bridging therapy for TPO-RA refractory pediatric ITP, offering hematological stabilization while reducing treatment burden. These findings address current evidence deficiencies in TPO-RA switching protocols.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, capecitabine / Generic mfg.
Journal: The Locally Active-Controlled Optimal Design: Applications in Oncology Clinical Studies. (Pubmed Central) - Nov 13, 2025
Our novel approach avoids unrealistic distributional assumptions about response measurements. The resulting locally AC-optimal design minimizes the variance of the estimated matching dose of Dalpiciclib to Capecitabine and may unify Phase II and Phase III objectives by allowing evaluation of a higher Dalpiciclib dose with prespecified
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Journal, Pan tumor: Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial. (Pubmed Central) - Nov 13, 2025
The resulting locally AC-optimal design minimizes the variance of the estimated matching dose of Dalpiciclib to Capecitabine and may unify Phase II and Phase III objectives by allowing evaluation of a higher Dalpiciclib dose with prespecified Pyrotinib demonstrated a favorable safety profile and modest efficacy in patients with previously treated HER2-positive advanced non-breast solid tumors.
- | Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Journal: Famitinib: First Approval. (Pubmed Central) - Nov 13, 2025
In May 2025, famitinib was granted conditional approval for use in combination with camrelizumab for the treatment of patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy and have not received prior bevacizumab in China. This article summarizes the milestones in the development of famitinib leading to this first approval for the treatment of recurrent or metastatic cervical cancer.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Review, Journal: Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis. (Pubmed Central) - Nov 13, 2025
This article summarizes the milestones in the development of famitinib leading to this first approval for the treatment of recurrent or metastatic cervical cancer. Camrelizumab combined with apatinib showed favorable efficacy and safety in the treatment of RM-NPC, providing an important reference for clinical treatment strategies.
- || Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
Trial completion: Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 12, 2025
P1, N=18, Completed, Sponsor: Lyudmila Bazhenova, M.D.
Camrelizumab combined with apatinib showed favorable efficacy and safety in the treatment of RM-NPC, providing an important reference for clinical treatment strategies. Active, not recruiting --> Completed
- | otesaconazole (VT-1161) / Mycovia Pharma, fluconazole oral / Generic mfg.
Journal: Synthesis, X-Ray Structure, Characterization, Antifungal Activity, DFT, and Molecular Simulation of a Novel Pyrazole Carboxylic Acid. (Pubmed Central) - Nov 12, 2025
The results suggest that compound L1 is a promising antifungal candidate, showing greater potential than fluconazole in the conducted evaluations. Further studies are warranted to explore its full therapeutic potential.
- | AiTan (rivoceranib) / HLB Bio Group, Cyramza (ramucirumab) / Eli Lilly, Fruzaqla (fruquintinib) / Takeda
Review, Journal, IO biomarker: Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer. (Pubmed Central) - Nov 10, 2025
The review also classifies and summarizes biomarkers with potential predictive value for treatment response, and discusses the current major challenges and potential optimization strategies. This analysis identifies significant gaps in predictive biomarkers and emphasizes that patient stratification and rational combination strategies are essential for optimizing therapeutic outcomes.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, vinorelbine tartrate / Generic mfg.
Retrospective data, Journal, Real-world evidence: Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study. (Pubmed Central) - Nov 10, 2025
No severe TAAEs were observed during the investigation. The triple regimen of inetetamab plus pyrotinib and vinorelbine exhibited promising therapeutic effects and was tolerable for participants with HER2-positive ABC.
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: Reduced Peripheral Blood Natural Killer Cell Proportion Predicts Poor Overall Survival in Advanced Gastric Cancer Patients Treated With Apatinib. (Pubmed Central) - Nov 10, 2025
Apatinib combined with S-1 exhibited favorable tolerability and promising clinical activity as a second-line option for AGC patients. Importantly, we identified peripheral blood NK cell proportion as a potential predictor of treatment response, where a low NK cell proportion correlated with poorer outcomes.
- HRS9531 injection / Kailera Therapeutics
Phase 3 Trial of HRS9531, a GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity (GWCC-A411-A412; Live In-Person; Virtual Conference) - Nov 9, 2025 - Abstract #OBESITYWEEK2025OBESITY_WEEK_698;
Importantly, we identified peripheral blood NK cell proportion as a potential predictor of treatment response, where a low NK cell proportion correlated with poorer outcomes. In this 48-week trial in Chinese adults with overweight or obesity, HRS9531 substantially reduced body weight and provided comprehensive metabolic improvements, with a well-tolerated safety profile.